Share-based Payment Arrangement, Expense of DICE Therapeutics, Inc. from 30 Sep 2020 to 30 Jun 2023

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
DICE Therapeutics, Inc. quarterly and annual Share-based Payment Arrangement, Expense in USD history and change rate from 30 Sep 2020 to 30 Jun 2023.
  • DICE Therapeutics, Inc. Share-based Payment Arrangement, Expense for the quarter ending 30 Jun 2023 was $5,503,000, a 31% increase year-over-year.
  • DICE Therapeutics, Inc. Share-based Payment Arrangement, Expense for the twelve months ending 30 Jun 2023 was $4,387,825, a 17% decline year-over-year.
  • DICE Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2022 was $12,825, a 130% increase from 2021.
  • DICE Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2021 was $5,581, a 99% decline from 2020.
Source SEC data
View on sec.gov
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Change (%)
Share-based Payment Arrangement, Expense, Annual (USD)
Share-based Payment Arrangement, Expense, YoY Annual Change (%)

DICE Therapeutics, Inc. Quarterly Share-based Payment Arrangement, Expense (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q2 2023 $4,387,825 $5,503,000 +$1,295,000 +31% 01 Apr 2023 30 Jun 2023 10-Q 08 Aug 2023 2023 Q2
Q1 2023 $3,092,825 $4,889,000 +$3,080,000 +170% 01 Jan 2023 31 Mar 2023 10-Q 11 May 2023 2023 Q1
Q4 2022 $12,825 $9,469,175 -$5,573,756 -143% 01 Oct 2022 31 Dec 2022 10-K 15 Mar 2023 2022 Q4
Q3 2022 $5,586,581 $3,465,000 +$307,000 +9.7% 01 Jul 2022 30 Sep 2022 10-Q 09 Nov 2022 2022 Q3
Q2 2022 $5,279,581 $4,208,000 +$3,812,000 +963% 01 Apr 2022 30 Jun 2022 10-Q 08 Aug 2023 2023 Q2
Q1 2022 $1,467,581 $1,809,000 +$1,462,000 +421% 01 Jan 2022 31 Mar 2022 10-Q 11 May 2023 2023 Q1
Q4 2021 $5,581 $3,895,419 01 Oct 2021 31 Dec 2021 10-K 15 Mar 2023 2022 Q4
Q3 2021 $3,158,000 +$3,157,851 +2119363% 01 Jul 2021 30 Sep 2021 10-Q 09 Nov 2022 2022 Q3
Q2 2021 $396,000 01 Apr 2021 30 Jun 2021 10-Q 11 Aug 2022 2022 Q2
Q1 2021 $347,000 01 Jan 2021 31 Mar 2021 10-Q 12 May 2022 2022 Q1
Q3 2020 $149* 01 Jul 2020 30 Sep 2020 10-Q 12 Nov 2021 2021 Q3

DICE Therapeutics, Inc. Annual Share-based Payment Arrangement, Expense (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2022 $12,825 +$7,244 +130% 01 Jan 2022 31 Dec 2022 10-K 15 Mar 2023 2022 FY
2021 $5,581 -$550,419 -99% 01 Jan 2021 31 Dec 2021 10-K 15 Mar 2023 2022 FY
2020 $556,000 01 Jan 2020 31 Dec 2020 10-K 28 Mar 2022 2021 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.